A 4-week, multicenter, double-blind, double-dummy, randomized, parallel group study to compare the gastrointestinal safety and tolerability of EC-MPS [enteric-coated mycophenolate sodium] and MMF [mycophenolate mofetil] when administered in combination with calcineurin inhibitors in renal transplant recipients experiencing gastrointestinal intolerance.

Trial Profile

A 4-week, multicenter, double-blind, double-dummy, randomized, parallel group study to compare the gastrointestinal safety and tolerability of EC-MPS [enteric-coated mycophenolate sodium] and MMF [mycophenolate mofetil] when administered in combination with calcineurin inhibitors in renal transplant recipients experiencing gastrointestinal intolerance.

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Aug 2011

At a glance

  • Drugs Mycophenolate mofetil; Mycophenolate sodium
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 12 Aug 2011 Actual end date changed from Sep 2006 to Oct 2006 as reported by ClinicalTrials.gov.
    • 12 May 2009 Actual end date (Jun 2008) added as reported by ClinicalTrials.gov.
    • 12 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top